OTCM
BVNRY
Market cap2.53bUSD
Oct 08, Last price
11.48USD
1D
3.52%
1Q
23.44%
Jan 2017
-0.61%
Name
Bavarian Nordic A/S
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in cancer immunotherapy including cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian, and prostate cancer. The company was founded on July 1, 1992 and is headquartered in Hellerup, Denmark.
Key people
Independent Chairman of the Board · since 2025
Paul Chaplin
President, Chief Executive Officer · since 2014
Heidi Hunter
Independent Vice Chairman of the Board · since 2025
Russell Thirsk
Executive Vice President, Chief Operating Officer · since 2022
Henrik Juuel
Executive Vice President, Chief Financial Officer · since 2018
Jean-Christophe May
Executive Vice President, Chief Commercial Officer · since 2020
Linette Andersen
Director, Employee Elected · since 2021
Thomas Bennekov
Director, Employee Elected · since 2021
Anja Gjol
Director, Employee Elected · since 2021
Karen Jensen
Director, Employee Elected · since 2021
Montse Montaner
Independent Director · since 2024
Johan van Hoof
Independent Director · since 2023
Independent Director · since 2016
IPO date
Nov 02, 1998
Employees
1,354
Domiciled in
DK
Incorporated in
DK
Headquarters & legal address
PHILIP HEYMANS ALLE 3
HELLERUP, 84 2900
DK
HELLERUP, 84 2900
DK
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||